LG Chem, Ltd

Products

FOLLITROPE® Prefilled Syringe Inj.

    • Product Name: FOLLITROPE® Prefilled Syringe Inj.
    • Chemical Name (IUPAC): follitropin alfa
    • CAS No.: 145336-22-3
    • Chemical Formula: C1001H1529N263O300S9
    • Form/Physical State: Solution for injection
    • Factroy Site:
    • Price Inquiry: sales6@ascent-chem.com
    • Manufacturer: LG Chem, Ltd
    • CONTACT NOW
    VTB
    Specifications
    HS Code 338523
    Brand Name FOLLITROPE® Prefilled Syringe Inj.
    Active Ingredient Follitropin alfa
    Drug Class Recombinant human follicle stimulating hormone (FSH)
    Formulation Prefilled syringe for injection
    Indication Infertility treatment (controlled ovarian stimulation)
    Route Of Administration Subcutaneous injection
    Available Strengths Typically 75 IU, 150 IU, 300 IU per syringe
    Manufacturer LG Chem
    Prescription Status Prescription only
    Storage Conditions Store at 2°C to 8°C (refrigerated)
    Shelf Life 2 years (check product packaging for exact expiry)
    Common Side Effects Headache, abdominal pain, ovarian hyperstimulation, injection site reactions
    Country Of Origin South Korea

    As an accredited FOLLITROPE® Prefilled Syringe Inj. factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing FOLLITROPE® Prefilled Syringe Inj. packaging features a white box with blue accents, containing 1 prefilled syringe (75 IU/0.5 mL).
    Container Loading (20′ FCL) Container Loading (20′ FCL) for FOLLITROPE® Prefilled Syringe Inj.: Securely packed in insulated cartons on pallets, temperature-controlled transport ensured.
    Shipping FOLLITROPE® Prefilled Syringe Inj. is shipped in temperature-controlled packaging to maintain stability, typically at 2–8°C (refrigerated). It is protected from light and excessive vibration. The packaging is clearly labeled as a pharmaceutical product, with appropriate documentation and handling instructions for safe, secure, and compliant delivery to medical facilities or pharmacies.
    Storage FOLLITROPE® Prefilled Syringe Inj. should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect the medication from light and do not freeze. Keep the syringe in its original packaging until use. If necessary, it may be stored at room temperature (below 25°C/77°F) for up to 28 days, after which any unused product should be discarded.
    Shelf Life FOLLITROPE® Prefilled Syringe Injection has a shelf life of 24 months when stored refrigerated at 2-8°C, protected from light.
    Application of FOLLITROPE® Prefilled Syringe Inj.

    Applications of FOLLITROPE® Prefilled Syringe Inj. in Industrial Manufacturing

    FOLLITROPE® Prefilled Syringe Injection is a recombinant human follicle-stimulating hormone (rhFSH) product, extensively used as an active pharmaceutical ingredient (API) and as a constitutive element in advanced fertility treatment manufacturing lines. Its industrial application is tightly bound to regulated biotechnological, reproductive medicine, and clinical pharmacy sectors, with each scenario governed by rigorous industry standards, precise formulation practices, and integrated GMP compliance from synthesis to packaging.

    1. Infertility Treatment Drug Manufacturing

    Global pharmaceutical companies produce injectable gonadotropin formulations for controlled ovarian stimulation using rhFSH as the main active ingredient. In such applications, the raw material is processed under validated biopharmaceutical lines, focusing on purity, bioactivity, and precise dosage accuracy for use in both in-vitro fertilization (IVF) and other assisted reproductive technologies (ART). Formulators adjust the rhFSH concentration based on regional labeling, clinical trial data, and regulatory needs. The API enters primarily during the aseptic compounding and fill-finish steps to ensure bioburden control and potency integrity. The resulting products are final-dose injectable medications supplied to medical centers and clinics globally.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    2. Reproductive Endocrinology Research Kits Assembly

    Manufacturers that supply research-use-only (RUO) diagnostic kits for hormonal profiling and receptor ligand studies integrate rhFSH in purified, lyophilized, or buffered forms. The primary application involves reagent assembly for bioactivity assays and hormone receptor response validation within preclinical research. Operators dose rhFSH in line with the requirements of detection thresholds and research grade specifications. The integration point consistently occurs in final formulation and lyophilization stages, utilizing isolate and dispensation equipment ensuring consistent batch reproducibility. Finished products cater to universities, research institutes, and reproductive medicine laboratories.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    3. Hospital Compounding Center Bulk Supply

    Compounding facilities in large hospitals or licensed sterile pharmacies require bulk-grade rhFSH to formulate custom fertility treatment regimens for patient-specific protocols. Bulk API gets delivered in lyophilized form and introduced into controlled compounding cleanroom suites. Technicians reconstitute and dilute the material according to individual prescription parameters, adhering to validated stability and dose adjustment procedures. Integration points include precision blending, aliquoting, and aseptic transfer into unit-dose sterile syringes or infusion bags tailored for immediate clinical use.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    4. Contract Development and Manufacturing Organization (CDMO) Fill-Finish

    Specialized CDMOs serving biotech and pharmaceutical clients utilize rhFSH as a primary API in small- and large-scale fill-finish projects. The raw material is introduced post-sterile filtration during bulk solution preparation, under GMP environmental controls, ensuring accuracy through automated dosing systems. Adjustments to fill concentrations occur per sponsor dossier requirements, with in-process quality control verifying both bioactivity and protein content. Final fill-finished products consist of stable, market-ready formats exported to clinical study sponsors and hormone therapy providers.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    Free Quote

    Competitive FOLLITROPE® Prefilled Syringe Inj. prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.

    We will respond to you as soon as possible.

    Tel: +8618018036652

    Email: sales6@ascent-chem.com

    Inquiry

    Get Free Quote of LG Chem, Ltd

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Introducing FOLLITROPE® Prefilled Syringe Inj.

    Direct from the Manufacturer: A New Standard for Recombinant Human Follicle Stimulating Hormone (rhFSH)

    At our plant, talk of continuous improvement runs alongside the steady hum of our lines. If you visit during production days, you’ll spot our teams focused on one thing: reliability from batch to batch. FOLLITROPE® Prefilled Syringe Inj. came out of years of close work with endocrinologists, fertility clinic staff, and patients themselves. We do not simply put out another rhFSH — we shaped this offering based on stories from clinics and voices from patients who wanted dosing they could handle themselves, with every precaution against contamination or error.

    We made FOLLITROPE® without cutting corners. The process relies on advanced mammalian cell lines, which deliver consistent glycosylation and purity for the recombinant human follicle stimulating hormone. Technicians check for impurities long before anything fills a syringe. No question, recombinant production offers a different level of traceability compared to earlier extraction-based options – over the years, our QA team traced every lot to individual vials and kept audits open to regulators. Hospitals need that kind of transparency, and batch-specific records come standard from our facility.

    Specifications and Dosing Model

    Every FOLLITROPE® Prefilled Syringe ships in measured, ready-for-use units. Dosing generally reflects what clinic staff tell us works best for controlled ovarian stimulation in women undergoing assisted reproductive techniques. We see frequent orders for 75, 150, 225 IU prefilled syringes, based on individualized regimens—our filling equipment adapts for custom pack sizes down to the smallest run, a practice we started after seeing clinics struggle with rigid packaging from other brands.

    Needles come attached or separately packed, depending on what physicians and nurses prefer for each clinic. The single-use glass barrel, rubber stopper, and luer lock draw on medical-grade materials sourced through validated supply chains. Fill weight, vacuum integrity, and sterility go through multiple checks before any unit ships. What goes out the door carries batch and expiration labels printed onsite. There is no room for errors in fertility care. The real-world result: clinics open a box, hand a dose to a patient, and patients inject with assurance.

    Clinical Usage in Fertility Care

    We see first-hand how FOLLITROPE® supports ovarian follicular development when used as part of assisted reproductive cycles such as in vitro fertilization. Over the past decade, many clinics have moved away from urinary-derived gonadotropins, citing inconsistent activity and risk of protein contamination. Our partners asked for a product with recombinant purity, and we delivered with FOLLITROPE®, following international GMP standards.

    Patients value the comfort that comes with precision dosing and prefilled convenience. The small but meaningful detail of a smooth-glide plunger, designed not to stick even at low temperatures, comes directly from feedback. Less discomfort translates into fewer abandoned cycles, especially for those juggling multiple hormone injections through a long IVF protocol. Our teams adapted the buffer composition and excipients based on stability results under both domestic and international storage conditions. Clinics do not face last-minute cold chain crises because every lot gets stress-tested before delivery.

    Improvements Over Traditional and Competing Products

    Hospitals and fertility centers no longer face uncertainty that can come with older urinary-extracted FSH or generic alternatives. Extraction-based products can vary considerably lot to lot in glycosylation and protein content—clinicians saw odd stimulation patterns and struggled to adjust doses on cycles. We put that behind us with FOLLITROPE®. Our recombinant FSH matches the structure of endogenous hormone, so patients receive consistent clinical response. Accuracy in dosing leads to predictable ovarian response, less cycle to cycle fluctuation, and clinic teams see the shift in both clinical success rates and patient satisfaction.

    We also get fewer reports of injection-site discomfort. By refining excipients down to approved stabilizers, we cut out additives causing irritation. Before the switch, clinics reported clustered site reactions with products that used animal-derived stabilizers—our move to human-compatible ingredients sharply reduced downtime for affected patients. Over the years, our support desk heard fewer complaints about adverse reactions, and patient instructions became simpler: open, inject, dispose safely.

    No less important is the design change in the plunger and barrel. Earlier syringe models from other brands caused variable dispersion, with patients struggling to control the last portion of the dose. By working with our molding partners, we built in a guide that eliminates that worry. What sounds like a small step, like a plunger upgrade, often reflects months of patient feedback and repeated trials inside both manufacturing and clinic test runs.

    Transparency and Traceability – Keeping Patients and Clinics Confident

    There have been cases, widely covered in industry news, of impurities showing up in certain old-generation FSH batches, resulting in urgent batch recalls. Our company doubled down on traceability. FOLLITROPE® production lines run automated tracking for every unit, with real-time digital logs linking raw material lots, fill lines, and QA sign-off for rapid response if any issue arises. Each prefilled syringe carries a unique identifier. If there is a question, our QA professionals can pinpoint the batch within minutes.

    During audits, everything opens up: batch records, sterility monitoring data, line logs, end-of-line microbiology. We invite regulatory inspectors to walk the process and retrace every step, so the reassurance isn’t just a promise. We extend this to clinicians as well: detailed CoAs and validation data go with every shipment, not because regulations require it, but because fertility patients and providers deserve as much peace of mind as we can offer. For those using imported or gray-market FSH, this level of transparency rarely occurs. Direct supply from an established manufacturer makes a visible difference.

    Supporting Clinics and Patients in Real-World Contexts

    We have welcomed doctors, nurses, and even patients to tour our facility. Many find reassurance in seeing exactly where FOLLITROPE® syringes come off the line. More than a few patients have written that the most stressful part of fertility care isn’t always the treatment, but confusion or fear around medicine handling. A clear prefilled design takes that guesswork away, sparing both clinician and patient from dosage errors. Distribution centers run regular training for clinic staff, and each box ships with printed, illustrated guides reflecting best practices based on international treatment protocols.

    Complex scheduling and variable ovarian responses make flexibility crucial for providers. Our system accepts small or custom runs so clinics never face overstock or wastage. As a direct supplier, we stay in constant contact with end users—if a provider wants a format we haven’t produced before, engineers and formulation experts review the request, and pilot production shifts start immediately. Competing brands often can’t match this responsiveness because of outsourced manufacturing or stock limitations.

    Insurance companies and government health schemes review our detailed documentation for each product cycle. We maintain clear pharmacoeconomic files outlining resource savings achieved by fewer lost cycles, reduced need for repeat stimulation, and simplified administration vs. off-label or compounded hormone approaches. As a direct manufacturer, our role extends past the factory gate—every improvement in the supply chain, packaging integrity, or clinical usability emerges from hands-on work with real-world partners.

    Commitment to Safety—Every Batch, Every Dose

    We commit to the same vigilance for every lot, whether it ships to urban IVF clinics or rural satellite centers. The safety profile of recombinant FSH depends on technical details hidden from patients—cell line stability, purification technology, filling accuracy at microgram scale, sterility control—but the benefit shows up with every consistent, successful cycle. Suppliers of animal- or urine-derived products sometimes struggle to guarantee all that, even with upgrades in screening and filtration.

    Every FOLLITROPE® batch goes through viral clearance validation, including multiple filtration and inactivation steps. Third-party labs conduct independent reviews of our retention samples, not out of obligation, but out of commitment to patient safety. If a change occurs in cell culture media or filling equipment, no product reaches the market until new validation closes. Our safety standards do not shift with trends—the procedures go through regulatory inspection, scientific publication, and frequent scrutiny from both our internal experts and outside authorities.

    Reducing Barriers, Enhancing Access

    Our experience in fertility medicine manufacturing has taught us about more than just protein chemistry or cleanroom operations. The people we serve face high emotional and financial hurdles. FOLLITROPE®’s simplified, prefilled approach lowers some of these, eliminating vials, mixing steps, and confusion with multi-part packaging common in generic FSH. Elderly or anxious users handle an injection without technical support. We respond to repeated feedback that complicated dosing or last-minute mixing causes dropped cycles or dose timing errors—every simplification we design in means fewer obstacles in practice.

    Through direct partnerships with clinics and payers, we have also worked out pricing models that avoid markup from third parties. Many patients now ask about rebate programs, direct-to-clinic pricing, or patient access programs. Because we handle direct distribution, we set up these support programs in real time, adjusting inventory or price bands to align with insurance changes or government guidelines. This speaks to our philosophy: the manufacturer’s job does not end at quality control, but with accessible treatment for those facing infertility.

    Sustainability and Supply Security

    Recent years have brought sudden shortages and supply disruptions for various injectable medications, including gonadotropins. Our facility operates multisource production lines for rhFSH, with backup systems in sterile filling, cold chain logistics, and raw material storage. The company’s size is not as important as our planning: raw materials track through blockchain systems, and we maintain dual sourcing for cell culture media, glass, and major excipients. Every annual review builds in redundancy.

    We share our monthly stock and forecast reports with partner clinics, not hiding supply gaps or shipment delays. Outages undercut treatment and trust, and as a manufacturer we place high priority on advance notice and rapid adjustment if market shifts or regulatory changes affect availability. This open-book approach in supply management builds trust and cuts down on last-minute emergencies for clinical partners.

    Conclusion: Shaping the Future of Fertility Treatments from the Factory Floor

    As a manufacturing company, you learn that advances in biotechnology don’t always show up in glossy brochures but in the everyday practice of healthcare teams and in the real lives of patients. FOLLITROPE® Prefilled Syringe Inj. stands apart because we crafted each design detail, production control, and support service from decades of hands-on work. Hospitals, clinics, and most of all, families searching for a path to parenthood, trust our teams because everything—product, paperwork, batch, and advice—comes straight from source.

    No generic or third-party importer can match our offering, because we welcome every audit, rethink every batch, and adapt as medicine changes. Our commitment is not only to clinical precision, but to open, responsive partnership with those depending on safe, consistent, and convenient fertility therapeutics. With every FOLLITROPE® syringe, our signature means more than a brand—it stands for a manufacturing promise delivered, from the cleanroom to the clinic, and into the hands of those hoping to change their lives.